Stereotactic radiofrequency pallidotomy with microelectrode mapping for Parkinson's disease
Customize your policy alerts
Sign up for DHA Policy 4.0 alerts
Get alerted when Policy 4.0 changes without checking for updates manually.
Monitor payer policy activity
This policy section addresses stereotactic radiofrequency pallidotomy with microelectrode mapping as a surgical treatment for Parkinson's disease under the DHA surgery policy manual. The substantive coverage criteria and operational requirements are not present in this document window.
No material clinical or coverage changes in this revision.
Covered Indication and Clinical Exclusions
Covered indication
Pallidotomy may be cost-shared when the following condition is met:
This criterion applies to pallidotomy for Parkinson's disease.
Cost-sharing is excluded for patients exhibiting signs of early dementia.
Cost-sharing is excluded for elderly patients with very advanced disease accompanied by autonomic symptoms or severe speech impairment.
Cost-sharing is excluded for patients with Parkinson's Plus syndrome that mimics true Parkinson's disease, including postural instability, freezing, poor speech volume, or swallowing difficulties.
Covered Procedure Code
| 61720 | Stereotactic radiofrequency pallidotomy with microelectrode mapping for treatment of Parkinson's disease |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.